Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

While the early week buzz centered around the U.S.-China trade agreement, another critical development unfolded quietly but ...

Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...

Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...

Less than 3% of all people in the U.S. who are eligible for injectable weight loss drugs get a prescription for it, a new ...

Point32Health, the owner of Harvard Pilgrim Health Care and Tufts Health Plan, will dramatically change how and when it pays for Zepbound— the insurer’ s preferred GLP-1 weight-loss drug— when used to ...

“I’m down about 50 pounds. I want to lose another 50,” Barkley said, revealing he gained 100 pounds after hip surgery. The target weight, he said, is 270 pounds. He said he is taking Zepbound, a ...

Shapiro, a Democrat who is considered a potential White House contender in 2028, said that if the cuts are made, the state would be unable to make up that amount of lost federal aid.

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...